Timothy P. Cooley, MD
Associate Professor
Boston University School of Medicine
Dept of Medicine
Hematology & Medical Oncology Section

MD, State University of New York at Buffalo



My areas of clinical specialty include lung cancer, head and neck cancer and the care of HIV infected people with cancer. My research interests are in clinical trials in hematology/oncology.

Active Staff Hospital Privileges
Boston Medical Center
Medicine




A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of GW433908 (700mg BID) plus Ritonavir (100mg BID) Versus Lopinavir/Ritonavir (400mg/100mg BID) when Administered in Combination with the Abacavir/Lamivudine (600mg/300mg)
08/23/2004 - 04/27/2006 (PI)
GlaxoSmithKline, Inc.

An Open-Label Phase III Study to Access the Long Term Safety Profile of GW433908 Containing Regimens in HIV-1 Infected Adults
05/10/2001 - 06/01/2004 (PI)
GlaxoSmithKline, Inc.

A Randomized Open Label Study of the Antiviral Efficacy and Safety of Atazanavir in Combination with Ritonavir or Saquinavir and the Combination of Lopinavir Ritonavir each with Tenofovir and a Nucleoside in Subjects who have Experienced virologic failure
12/01/2001 - 11/30/2003 (PI)
Bristol-Myers Squibb

A Phase III, Randomized, Multicenter, Parallel Group, Open-Label, Three Arm Study to Compare the Efficacy and Safety of Two Dosing Regimens of GW433908/ritonavir (700mg/100mg Twice Daily or 1400mg/200mg Once Daily) Versus Lopinavir/ritonavir (400mg/100mg
05/10/2001 - 12/31/2002 (PI)
GlaxoSmithKline, Inc.

An Open-Label Multinational Study of the Effects of Three Dose Pairs of Tipranavir/Ritonavir (BID) on the Pharmacokinetic Characteristics of Protocol Defined, Baseline, Triple Drug Nucleoside and Non Nucleoside Reverse Transcriptase Inhibitor Therapy in H
04/25/2001 - 12/31/2002 (PI)
Boehringer Ingelheim Pharmaceuticals

A Phase IV Multicenter Study of the Efficacy and Safety of 48 Week Induction Treatment with TRIZIVIR (Abacavir 300mg Lamivudine 150mg Zidovudine 300 mg Combination Tablet BID) + Efavirenz (600 mg QD) Followed by Randomized 48 Week Maintenance Treatment wi
03/15/2001 - 12/31/2001 (PI)
GlaxoSmithKline, Inc.

A 24-Week, Randomized, Open-label, Multicenter Trial to Compare the Safety and Efficacy of the Licensed Agenerase Dose (1200 mg BID) to a lower Agenerase dose (600 mg BID) in the presence of Norvir (100 mg BID) when combined with other background antiretr
07/01/2000 - 12/31/2001 (PI)
Kern McNeill International

A Phase III, Double Blind, Randomized, Multicenter Study of the Treatment of Antiretroviral Naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination with Lamivudine and Efavirenz Versus Stavudine, Lamivudine, and
06/16/2000 - 12/31/2001 (PI)
Gilead Sciences, Inc.

A Randomized, Open Label, Phase III Study of ABT/Ritonavir in Combination with Nevirapine and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) vs. Investigator Selected Protease Inhibitor(s) in Combination with Nevirapine and Two NRTIs in Antiretro
07/21/1999 - 12/31/2001 (PI)
PPD Pharmaco Inc Abbott Laboratories

A Phase IV 48 Week, Randomized, Open Label , Multicenter Trial of Abacavir (300 mg BID)/Efavirenz (600 mg QD)/(Didanosine (400 mg QD) +_ Hydroxyurea (600 mg BID) in HIV-1 Infected Subjects Failing Initial Therapy with Protease Inhibitor/3TC/ZDV (or d4T)
06/01/1999 - 12/31/2001 (PI)
Glaxo Wellcome Inc

Showing 10 of 13 results. Show All Results

SWOG - Clinical Trials Initiative
02/28/2009 - 02/28/2018 (PI)
South West Oncology Group NIH-NCI

SWOG Master Agreement
02/26/2014 - 02/25/2018 (PI)
Oregon Health and Science University NIH-NCI

American College of Surgeons Oncology Group (ACOSOG) Community Clinical Oncology Program (CCOP) Rese
03/29/2013 - 03/31/2016 (PI)
Mayo Clinic - Rochester NIH-NCI
5U10CA149950-02

Master Agreement - Alliance for Clinical Trials in Oncology Case Study Services
03/01/2014 - 02/28/2016 (PI)
Brigham & Women's NIH-NCI

NCCTG Research Base Agreement
04/09/2010 - 12/31/2015 (PI)
Mayo Clinic - Rochester NIH-NCI

Db Study Of Mkc-442
04/01/1998 - 08/31/2008 (PI)
TRIANGLE PHARMA, INC

Aids Clinical Trial
01/01/1997 - 12/31/2006 (PI)
Harvard Medical School NIH
5 U01 AI27659-17

Protocol Ftc303
09/21/1998 - 08/07/2005 (PI)
TRIANGLE PHARMA, INC

Boston Aids Malignancies Conso
08/01/1996 - 07/31/2005 (PI)
Mass General Hosp DHHS
5 U01 CA071375-09

Aids Clinical Trial
06/16/1999 - 12/31/2000 (PI)
Harvard Medical School

Showing 10 of 11 results. Show All Results


Yr Title Project-Sub Proj Pubs
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Unger JM, Hershman DL, Arnold KB, Loomba R, Chugh R, Hwang JP, O'Rourke MA, Bhadkamkar NA, Wang LX, Siegel AB, Cooley TP, Berenberg JL, Bridges BB, Ramsey SD. Stepwise development of a cancer care delivery research study to evaluate the prevalence of virus infections in cancer patients. Future Oncol. 2016 May; 12(10):1219-31. PMID: 26952901; PMCID: PMC4864045; DOI: 10.2217/fon-2015-0076;.
  2. Shah BA, Qureshi MM, Jalisi S, Grillone G, Salama A, Cooley T, Zaner K, Sakai O, Truong MT. Analysis of decision making at a multidisciplinary head and neck tumor board incorporating evidence-based National Cancer Comprehensive Network (NCCN) guidelines. Pract Radiat Oncol. 2016 Jul-Aug; 6(4):248-54.View Related Profiles. PMID: 26777060; DOI: 10.1016/j.prro.2015.11.006;.
  3. Castillo JJ, Bower M, Brühlmann J, Novak U, Furrer H, Tanaka PY, Besson C, Montoto S, Cwynarski K, Abramson JS, Dalia S, Bibas M, Connors JM, Furman M, Nguyen ML, Cooley TP, Beltran BE, Collins JA, Vose JM, Xicoy B, Ribera JM. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study. Cancer. 2015 Feb 1; 121(3):423-31. PMID: 25251326; DOI: 10.1002/cncr.29066;.
  4. Qureshi MM, Romesser PB, Jalisi S, Zaner KS, Cooley TP, Grillone G, Kachnic LA, Truong MT. The influence of limited English proficiency on outcome in patients treated with radiotherapy for head and neck cancer. Patient Educ Couns. 2014 Nov; 97(2):276-82.View Related Profiles. PMID: 25190640; DOI: 10.1016/j.pec.2014.07.031;.
  5. Yu J, Cooley T, Truong MT, Mercier G, Subramaniam RM. Head and neck squamous cell cancer (stages III and IV) induction chemotherapy assessment: value of FDG volumetric imaging parameters. J Med Imaging Radiat Oncol. 2014 Feb; 58(1):18-24.View Related Profiles. PMID: 24529051; DOI: 10.1111/1754-9485.12081;.
  6. Boehmer U, Cooley TP, Clark MA. Cancer and men who have sex with men: a systematic review. Lancet Oncol. 2012 Dec; 13(12):e545-53.View Related Profiles. PMID: 23182195; DOI: 10.1016/S1470-2045(12)70347-9;.
  7. Levine AM, Noy A, Lee JY, Tam W, Ramos JC, Henry DH, Parekh S, Reid EG, Mitsuyasu R, Cooley T, Dezube BJ, Ratner L, Cesarman E, Tulpule A. Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047. J Clin Oncol. 2013 Jan 1; 31(1):58-64. PMID: 23169503; PMCID: PMC3530691; DOI: 10.1200/JCO.2012.42.4648;.
  8. Agarwal A, Mehta A, Logeswaran P, Cooley TP, Subramaniam RM. Radiology quiz case 2. Docetaxel (Taxotere)-induced photosensitivity. Arch Otolaryngol Head Neck Surg. 2012 Sep; 138(9):869-70. PMID: 22986725; DOI: 10.1001/archoto.2012.1675;.
  9. Bayraktar UD, Ramos JC, Petrich A, Gupta N, Lensing S, Moore PC, Reid EG, Aboulafia DM, Ratner L, Mitsuyasu R, Cooley T, Henry DH, Barr P, Noy A. Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium. Leuk Lymphoma. 2012 Dec; 53(12):2383-9. PMID: 22642936; PMCID: PMC3458169; DOI: 10.3109/10428194.2012.697559;.
  10. Davison JM, Subramaniam RM, Surasi DS, Cooley T, Mercier G, Peller PJ. FDG PET/CT in patients with HIV. AJR Am J Roentgenol. 2011 Aug; 197(2):284-94.View Related Profiles. PMID: 21785073; DOI: 10.2214/AJR.10.6332;.
Showing 10 of 45 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 45 publications over 27 distinct years, with a maximum of 4 publications in 1993 and 2002 and 2012

YearPublications
19882
19903
19912
19922
19934
19941
19952
19961
19971
19981
19992
20001
20012
20024
20031
20041
20061
20071
20081
20091
20101
20111
20124
20131
20142
20151
20161
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

AIDS
Cancer Clinical Trials
Head and neck cancer
Lung cancer

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Education Mentor
  • Research / Scholarly Mentor
Contact for Mentoring:


820 Harrison Ave
Boston MA 02118
Google Map


Cooley's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department